Literature DB >> 15014128

Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice.

Walter J Brecht1, Faith M Harris, Shengjun Chang, Ina Tesseur, Gui-Qiu Yu, Qin Xu, Jo Dee Fish, Tony Wyss-Coray, Manuel Buttini, Lennart Mucke, Robert W Mahley, Yadong Huang.   

Abstract

Apolipoprotein E (apoE) is found in amyloid plaques and neurofibrillary tangles (NFTs) in Alzheimer's disease (AD) brains, but its role in their pathogenesis is unclear. Previously, we found C-terminal-truncated fragments of apoE in AD brains and showed that such fragments can cause neurodegeneration and can induce NFT-like inclusions in cultured neuronal cells and in transgenic mice. Here, we analyzed apoE fragmentation in brain tissue homogenates from transgenic mice expressing apoE3 or apoE4 in neurons [neuron-specific enolase (NSE)-apoE] or astrocytes [glial fibrillary acidic protein (GFAP)-apoE] by Western blotting. The C-terminal-truncated fragments of apoE accumulated, in an age-dependent manner, in the brains of NSE-apoE4 and, to a significantly lesser extent, NSE-apoE3 mice; however, no fragments were detected in GFAP-apoE3 or GFAP-apoE4 mice. In NSE-apoE mice, the pattern of apoE fragmentation resembled that seen in AD brains, and the fragmentation was specific for certain brain regions, occurring in the neocortex and hippocampus, which are vulnerable to AD-related neurodegeneration, but not in the less vulnerable cerebellum. Excitotoxic challenge with kainic acid significantly increased apoE fragmentation in NSE-apoE4 but not NSE-apoE3 mice. Phosphorylated tau (p-tau) also accumulated in an age-dependent manner in NSE-apoE4 mice and, to a much lesser extent, in NSE-apoE3 mice but not in GFAP-apoE3 or GFAP-apoE4 mice. Intraneuronal p-tau inclusions in the hippocampus were prominent in 21-month-old NSE-apoE4 mice but barely detectable in NSE-apoE3 mice. Thus, the accumulation of potentially pathogenic C-terminal-truncated fragments of apoE depends on both the isoform and the cellular source of apoE. Neuron-specific proteolytic cleavage of apoE4 is associated with increased phosphorylation of tau and may play a key role in the development of AD-related neuronal deficits.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15014128      PMCID: PMC6729489          DOI: 10.1523/JNEUROSCI.4315-03.2004

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  65 in total

1.  Expression of human apolipoprotein E3 or E4 in the brains of Apoe-/- mice: isoform-specific effects on neurodegeneration.

Authors:  M Buttini; M Orth; S Bellosta; H Akeefe; R E Pitas; T Wyss-Coray; L Mucke; R W Mahley
Journal:  J Neurosci       Date:  1999-06-15       Impact factor: 6.167

2.  Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity.

Authors:  M Tolar; J N Keller; S Chan; M P Mattson; M A Marques; K A Crutcher
Journal:  J Neurosci       Date:  1999-08-15       Impact factor: 6.167

Review 3.  Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond.

Authors:  R W Mahley; Y Huang
Journal:  Curr Opin Lipidol       Date:  1999-06       Impact factor: 4.776

4.  Apolipoprotein E and cognitive performance.

Authors:  J Raber; D Wong; G Q Yu; M Buttini; R W Mahley; R E Pitas; L Mucke
Journal:  Nature       Date:  2000-03-23       Impact factor: 49.962

5.  Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice.

Authors:  I Tesseur; J Van Dorpe; K Spittaels; C Van den Haute; D Moechars; F Van Leuven
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

6.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease.

Authors:  K R Bales; T Verina; D J Cummins; Y Du; R C Dodel; J Saura; C E Fishman; C A DeLong; P Piccardo; V Petegnief; B Ghetti; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

7.  Sialylated human apolipoprotein E (apoEs) is preferentially associated with neuron-enriched cultures from APOE transgenic mice.

Authors:  P T Xu; D Schmechel; H L Qiu; M Herbstreith; T Rothrock-Christian; M Eyster; A D Roses; J R Gilbert
Journal:  Neurobiol Dis       Date:  1999-02       Impact factor: 5.996

8.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.

Authors:  D M Holtzman; K R Bales; T Tenkova; A M Fagan; M Parsadanian; L J Sartorius; B Mackey; J Olney; D McKeel; D Wozniak; S M Paul
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

9.  Apolipoprotein E expression by neurons surviving excitotoxic stress.

Authors:  U Boschert; E Merlo-Pich; G Higgins; A D Roses; S Catsicas
Journal:  Neurobiol Dis       Date:  1999-12       Impact factor: 5.996

10.  Specific regional transcription of apolipoprotein E in human brain neurons.

Authors:  P T Xu; J R Gilbert; H L Qiu; J Ervin; T R Rothrock-Christian; C Hulette; D E Schmechel
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

View more
  170 in total

1.  Association of APOE with tau-tangle pathology with and without β-amyloid.

Authors:  Jose M Farfel; Lei Yu; Philip L De Jager; Julie A Schneider; David A Bennett
Journal:  Neurobiol Aging       Date:  2015-09-28       Impact factor: 4.673

Review 2.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

3.  Polymorphism of apolipoproteine E in relation with Alzheimer and vascular dementia.

Authors:  Zuzana Gdovinová; Viera Habalová; Zuzana Novosadová
Journal:  Cell Mol Neurobiol       Date:  2006-06-07       Impact factor: 5.046

4.  The efficiency of protein compartmentalization into the secretory pathway.

Authors:  Corinna G Levine; Devarati Mitra; Ajay Sharma; Carolyn L Smith; Ramanujan S Hegde
Journal:  Mol Biol Cell       Date:  2004-10-20       Impact factor: 4.138

5.  Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity.

Authors:  Shengjun Chang; Tian ran Ma; R Dennis Miranda; Maureen E Balestra; Robert W Mahley; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

6.  Rosiglitazone increases dendritic spine density and rescues spine loss caused by apolipoprotein E4 in primary cortical neurons.

Authors:  Jens Brodbeck; Maureen E Balestra; Ann M Saunders; Allen D Roses; Robert W Mahley; Yadong Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-22       Impact factor: 11.205

7.  Cognitive deficits and disruption of neurogenesis in a mouse model of apolipoprotein E4 domain interaction.

Authors:  Samuel O Adeosun; Xu Hou; Baoying Zheng; Craig Stockmeier; Xiaoming Ou; Ian Paul; Thomas Mosley; Karl Weisgraber; Jun Ming Wang
Journal:  J Biol Chem       Date:  2013-12-09       Impact factor: 5.157

8.  Human apolipoprotein E4 worsens acute axonal pathology but not amyloid-β immunoreactivity after traumatic brain injury in 3xTG-AD mice.

Authors:  Rachel E Bennett; Thomas J Esparza; Hal A Lewis; Eddie Kim; Christine L Mac Donald; Patrick M Sullivan; David L Brody
Journal:  J Neuropathol Exp Neurol       Date:  2013-05       Impact factor: 3.685

9.  GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice.

Authors:  Gang Li; Nga Bien-Ly; Yaisa Andrews-Zwilling; Qin Xu; Aubrey Bernardo; Karen Ring; Brian Halabisky; Changhui Deng; Robert W Mahley; Yadong Huang
Journal:  Cell Stem Cell       Date:  2009-12-04       Impact factor: 24.633

Review 10.  Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.

Authors:  Yang Shi; David M Holtzman
Journal:  Nat Rev Immunol       Date:  2018-12       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.